{"product_id":"henlius-business-model-canvas","title":"Shanghai Henlius Biotech Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech Business Model Canvas: commercialization, R\u0026amp;D focus, revenue pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDive into Shanghai Henlius Biotech’s strategic playbook with our Business Model Canvas — a concise view of its value propositions, partner ecosystem, and commercialization pathways. This snapshot highlights revenue streams, cost structure, and R\u0026amp;D priorities to inform investment or strategic decisions. Purchase the full, editable Canvas (Word\/Excel) for a section-by-section roadmap you can apply immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal pharma licensing allies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal pharma licensing allies co-develop and out-license Henlius biosimilars and biologics to expand reach; Henlius (2696.HK) leveraged partners to commercialize HLX02 (trastuzumab biosimilar) after NMPA approval in 2019 and EMA acceptance in 2020. Partnerships grant access to established brands, regulatory expertise and commercial infrastructures, share development risk, and accelerate entry into regulated and emerging markets, enabling indication expansion and lifecycle management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs and clinical sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartner with leading CROs and tertiary hospitals to run coordinated multi-center trials, improving patient recruitment, data quality, and geographic diversity while ensuring ICH-GCP and regional regulatory compliance; this strategy aims to compress timelines across Phase I through post-marketing studies and accelerate evidence generation for regulatory submissions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuppliers and CDMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShanghai Henlius secures high-quality cell lines, media, resins and single-use systems via preferred suppliers and validated QAs, supporting GMP continuity and cost efficiency; in 2024 Henlius reported revenue of RMB 2.5 billion reinforcing supplier leverage. The company uses CDMOs for surge capacity and specialized steps to accelerate launches and capex flexibility. Dual sourcing and contractual quality agreements reduce supply risk and protect manufacturing timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors and tender agents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHenlius leverages national and provincial distributors and tender agents to secure hospital listings, navigating centralized procurement and complex tender timelines to maximize formulary access. Partnerships prioritize expansion into lower-tier Chinese cities and export markets while aligning pricing and reimbursement strategies with provincial tender outcomes. Demand forecasting is coordinated with distributors to optimize production and margin management.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDistributor networks: hospital listings\u003c\/li\u003e\n\u003cli\u003eTender navigation: centralized procurement\u003c\/li\u003e\n\u003cli\u003eGeographic expansion: lower-tier cities \u0026amp; exports\u003c\/li\u003e\n\u003cli\u003eCommercial ops: pricing, reimbursement, forecasting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademia and technology partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShanghai Henlius leverages academia and tech partners to co-develop novel targets, assays and advanced analytics, accessing cutting-edge platforms such as high-throughput screening (\u0026gt;100,000 samples\/day) and AI-augmented CMC workflows that can cut development cycles by ~30%; IP is shared under clear licensing frameworks to expand the pipeline from biosimilars into innovative biologics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCollaborative target discovery\u003c\/li\u003e\n\u003cli\u003eHTS \u0026gt;100,000\/day\u003c\/li\u003e\n\u003cli\u003eAI-augmented CMC (~30% time reduction)\u003c\/li\u003e\n\u003cli\u003eClear IP licensing\u003c\/li\u003e\n\u003cli\u003ePipeline expansion: biosimilars → innovative biologics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar firm leverages global licensing and CDMO\/CRO partners, \u003cstrong\u003eRMB2.5bn\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius leverages global pharma licensing to commercialize biosimilars (HLX02: NMPA 2019, EMA 2020), partners with CROs and tertiary hospitals for multi-center trials, secures suppliers and CDMOs for GMP continuity and surge capacity, and uses distributors\/tender agents for hospital listings; 2024 revenue RMB 2.5 billion underpins partner leverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003eMarket access \u0026amp; out-license\u003c\/td\u003e\n\u003ctd\u003eHLX02 approvals; revenue base RMB 2.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Shanghai Henlius Biotech detailing customer segments, channels, value propositions, revenue streams, key activities, partners, resources, cost structure, and customer relationships aligned with its biologics development and commercialization strategy. Ideal for investor presentations, it includes competitive advantage analysis and linked SWOT insights to support strategic decisions and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Shanghai Henlius Biotech’s business model with editable cells, quickly pinpointing R\u0026amp;D, commercialization, and partnership gaps to relieve strategic planning and execution pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologics R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and optimize antibodies and fusion proteins, performing rigorous comparability for biosimilars and differentiation testing for novel assets; analytical, cell-based, and in vivo studies generate GLP\/GMP-grade data packages. Candidates progress through defined stage-gates with go\/no-go criteria, CMC comparability assessments, and regulatory-ready dossiers to support clinical and commercial milestones.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExecute Phase I–III trials and extrapolation strategies across a diversified pipeline, with over 20 clinical studies and \u0026gt;6,000 patients enrolled by 2024. Manage pharmacokinetics, immunogenicity, and robust efficacy endpoints with centralized labs and CRO partnerships. Conduct risk management plans and real-world evidence programs; support global submissions across Asia, EU and US regulatory pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ecGMP manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eScale upstream and downstream reliably across multi-10,000 L cGMP suites to support commercial supply; industry titers now routinely exceed 5 g\/L, enabling higher throughput. Validate processes, cleaning and aseptic ops with full qualification and batch‑level serialization for regulatory traceability. Maintain QA\/QC and batch release controls; process intensification has cut COGS by up to 30% in recent programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHenlius prepares CTD dossiers and manages NMPA and global agency interactions to secure approvals and hospital\/NRDL listings, leveraging accelerated review pathways (median review timelines near 12 months in 2024) to speed market entry. It runs national tender and HTA-aligned pricing strategies—tender-driven price cuts ~50%—while handling reimbursement dossiers. Continuous pharmacovigilance monitors safety signals, compiles PSURs and risk management with dedicated PV teams.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCTD preparation \u0026amp; agency liaison\u003c\/li\u003e\n\u003cli\u003eApprovals, NRDL\/listings, reimbursement\u003c\/li\u003e\n\u003cli\u003ePV, PSURs, signal management\u003c\/li\u003e\n\u003cli\u003ePricing tuned to tenders (~50% cuts) \u0026amp; HTA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCommercial execution runs medical education and KAM engagement, manages hospital inclusion, tenders and distributor performance, executes patient support\/adherence programs, and forecasts demand with inventory control; China biologics market ~USD 40bn (2023) with biosimilars growing ~20% CAGR into 2024, driving intensified hospital tender activity.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRun medical education \u0026amp; KAM\u003c\/li\u003e\n\u003cli\u003eManage hospital inclusion, tenders, distributors\u003c\/li\u003e\n\u003cli\u003ePatient support \u0026amp; adherence programs\u003c\/li\u003e\n\u003cli\u003eDemand forecasting \u0026amp; inventory management\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScale antibodies: \u0026gt;20 trials, \u0026gt;6,000 pts; multi-10k L, titers \u0026gt;5 g\/L, COGS -30%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesign\/optimize antibodies and biosimilars with GLP\/GMP comparability; run \u0026gt;20 clinical studies (\u0026gt;6,000 patients by 2024) across Phases I–III. Operate multi‑10,000 L cGMP suites, titers \u0026gt;5 g\/L, process intensification cutting COGS up to 30%. Secure approvals (median review ~12 months in 2024), tender pricing (~50% cuts) and NRDL\/reimbursement.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2023\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical studies \/ patients\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20 \/ \u0026gt;6,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ecGMP scale \u0026amp; titers\u003c\/td\u003e\n\u003ctd\u003emulti-10,000 L \/ \u0026gt;5 g\/L\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS reduction\u003c\/td\u003e\n\u003ctd\u003eup to 30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina biologics market\u003c\/td\u003e\n\u003ctd\u003e~USD 40bn (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory review median\u003c\/td\u003e\n\u003ctd\u003e~12 months (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTender price cuts\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Shanghai Henlius Biotech Business Model Canvas shown here is the actual deliverable, not a mockup or sample. When you purchase, you’ll receive this exact document—complete, formatted and ready-to-edit. The full file is provided in Word and Excel formats for immediate use and presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674985087353,"sku":"henlius-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/henlius-business-model-canvas.png?v=1755799780","url":"https:\/\/portersfiveforce.com\/products\/henlius-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}